Related Experiment Videos
Prognosis and treatment of cardiomyopathy and myocarditis
Insights
Dilated cardiomyopathy and viral myocarditis prognosis varies. While some cases improve spontaneously, standard treatments focus on heart failure and arrhythmias, with beta blockade and transplantation emerging as future options.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Dilated cardiomyopathy (DCM) is a heterogeneous heart disorder with variable prognosis tied to clinical and hemodynamic severity.
- Acute viral myocarditis often has a good prognosis, but can progress to chronic myocardial disease.
Purpose of the Study:
- To review the prognosis and therapeutic modalities for dilated cardiomyopathy and viral myocarditis.
- To highlight emerging treatments such as beta blockade and cardiac transplantation for DCM.
- To discuss the management of acute and chronic viral myocarditis, including potential immunosuppressive therapy.
Main Methods:
- Literature review of studies on dilated cardiomyopathy and viral myocarditis.
- Analysis of current and potential future therapeutic strategies.
- Discussion of diagnostic criteria, including endomyocardial biopsy for chronic myocarditis.
Main Results:
- Spontaneous improvement occurs in 25% of dilated cardiomyopathy cases.
- Standard therapies for DCM are nonspecific, focusing on heart failure and arrhythmias.
- Chronic myocarditis management mirrors DCM, with immunosuppression considered for severe cases.
Conclusions:
- Prognosis for DCM and myocarditis is dependent on disease severity and specific abnormalities.
- Beta blockade and cardiac transplantation show promise for dilated cardiomyopathy.
- Further research is needed to clarify prognosis and the roles of beta blockade and immunosuppression.
Abstract:
Dilated cardiomyopathy is a heterogeneous group of disorders with a prognosis that is dependent upon the severity of presenting clinical and hemodynamic abnormalities. Although this condition is characterized by a high mortality, spontaneous improvement is noted in 25% of cases. Standard therapeutic modalities are nonspecific and consist of the therapy of congestive heart failure and ventricular arrhythmia. Recent studies suggest that beta blockade and cardiac transplantation may soon become accepted modalities in this condition. Acute viral myocarditis is a common disease that has a good prognosis, however occasionally progression to chronic myocardial disease has been identified. The therapy of acute viral myocarditis should be limited to symptomatic treatment, anti-coagulation, and bed rest. When chronic myocarditis is identified on endomyocardial biopsy in patients with heart failure of unknown cause, the treatment differs little from that of dilated cardiomyopathy with the exception that recognizing that efficacy has not been proven; immunosuppressive therapy may be added in life-threatening situations. Future studies will be directed at further clarification of the prognosis of each of these conditions with intensive evaluation of the role of beta blockade and immunosuppression.